The Business Case For Post-Grant Patent Review
Executive Summary
Counsels’ view of what inter parte reviews and other new procedures introduced by the America Invents Act mean to the biopharma industry.
You may also be interested in...
The Patent Trolls Are Coming...To Medtech
For years medical device makers have largely avoided one of the technology world’s biggest headaches: patent “troll” litigation, but that’s about to change. What medtech needs to do to fight the trolls.
Patent Trolls Eye Biotech Firms; New PTO Proceedings Are ‘Game Changer’
Patent review proceedings established by America Invents Act may become ‘close second’ to ANDA litigation as way to invalidate patents; industry calls for changes as patent claims are routinely struck down.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.